AlphaYou
Overview
Smart money at a glance
Filings to Sep 30, 2026Net buying: insiders sold $0 and bought $9.5M on the open market in 90 days (SEC Form 4). Congress: net selling of $90K to $323K in 180 days.
- Company insidersSEC Form 4, last 90 days
- +$9.5M netNet buying
- CongressSTOCK Act, last 180 days
- -$90K to -$323K netNet selling
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 7 added, 7 cutEven
Key stats
Fundamentals Sep 30- Open
- $44.15
- 52-wk high
- $105.65
- High
- $44.30
- 52-wk low
- $42.20
- Low
- $43.22
- Prev close
- $44.11
- Mkt cap
- $63.59B
- P/E
- 17.8x
- Volume
- 14.61M
- Fwd P/E
- 13.2x
- Beta
- 0.57
- P/S
- 3.0x
- P/B
- 2.6x
- Profit margin
- +17.5%
- Op margin
- +22.9%
- ROE
- +15.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about BSX filings
Are insiders buying or selling Boston Scientific Corp (BSX) stock?
Net buying: insiders sold $0 and bought $9.5M of BSX stock on the open market in the 90 days to Sep 30, 2026, according to SEC Form 4 filings. The largest was Mahoney, Michael F (Chairman, President & CEO), who bought $9M. The latest filing was on Aug 26, 2026.
Which members of Congress have traded BSX recently?
Rep. Kevin Hern (R) sold $50K to $100K on Sep 9, 2026, disclosed 16 days later. Rep. Kevin Hern (R) sold $50K to $100K on Sep 4, 2026, disclosed 21 days later. Rep. Kevin Hern (R) sold $1K to $15K on Sep 3, 2026, disclosed 22 days later. Rep. Kevin Hern (R) sold $1K to $15K on Sep 3, 2026, disclosed 22 days later. In total, 3 members disclosed 10 BSX trades with trade dates in the last 180 days, filed a median 23 days after trading.
How current is this BSX smart-money data?
This summary uses filings available on Sep 30, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net buying.
What funds are doing
Buys/Adds (1)
- TS
Two Sigma
$235.7M
added
Sells/Trims (2)
- VG
Viking Global
$239.3M
sold
- P7
Point72
$215.8M
trimmed
What insiders are doing
Buys (3)
- MS
Morano Susan E
$100K
bought
- HD
Habiger David C
$100K
bought
- MM
Mahoney Michael F
$9.0M
bought
What Congress is doing
How top traders are positioned
No tracked top-trader positions in BSX right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 3.6% above what analysts expected.
Earnings per share
$0.83 expected
Revenue
No comparable estimate
Reports Oct 28, 2026, in 28 days
Estimates as of Sep 30, 2026
EPS expected
$0.58 to $0.84
Revenue expected
23 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $5.07B | $5.29B | $5.20B | $5.44B |
| Cost of what it sold | $1.52B | $1.35B | $1.59B | $1.59B |
| Gross profit | $3.54B | $3.94B | $3.61B | $3.85B |
| What it spent | ||||
| Research and development | $514.0M | $569.0M | $516.0M | $554.0M |
| Sales and admin | $1.74B | $1.83B | $1.78B | $1.80B |
| Other operating costs | $237.0M | $328.0M | $244.0M | $313.0M |
| Total operating expenses | $2.49B | $2.73B | $2.54B | $2.67B |
| What was left | ||||
| Operating profit | $1.05B | $1.21B | $1.07B | $1.18B |
| Interest on debt | $87.0M | $90.0M | $90.0M | $96.0M |
| Profit before tax | $939.0M | $700.0M | $1.16B | $1.06B |
| Tax | $183.0M | $31.0M | -$176.0M | $155.0M |
| Net profit | $755.0M | $668.0M | $1.34B | $907.0M |
| EBITDA | $1.37B | $1.16B | $1.60B | $1.39B |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is mixed
FDA Finally Approves Watchman Device from Boston Scientific
BullishSep 27Stryker stock trades at USD 270.92, down 0.91 percent in New York trading
Leans bearishSep 25Expert Voices: HCA Healthcare physician shares how pulsed field ablation is transforming atrial fibrillation care
Leans bullishSep 25After cancer treatment, monitoring may reach patients without tumor tissue
NeutralSep 25Boston Scientific stock gains 2.06 percent ahead of the open
Leans bullishSep 25Boston Scientific stock faces a weaker 2026 growth outlook
Leans bearishSep 24Boston Scientific stock slips before the bell after September 23 decline
Leans bearishSep 24Wells Fargo Adjusts Price Target on Boston Scientific to $48 From $50, Keeps Equalweight Rating
Leans bearishSep 24
Macro
33 macro signals shaping BSX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results